Latest News in the pharma Industry

Research & Development

Researchers develop microneedle patch for flu vaccination

Researchers develop microneedle patch for flu vaccination

28 Jun 2017

The patch can dramatically reduce the cost of vaccination, as self-administration can eliminate the need to have health workers oversee the process.

Read more 
Merck's anacetrapib meets primary endpoint

Merck's anacetrapib meets primary endpoint

28 Jun 2017

Company to consider whether to file new drug applications with the FDA and other regulatory agencies.

Read more 
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS

Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS

25 Jun 2017

Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.

Read more 
Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer

Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer

25 Jun 2017

New indication supported by results of Phase III PALOMA-3 Trial of Ibrance in combination with fulvestrant.

Read more 
Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMP

Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMP

23 Jun 2017

If approved, Imraldi will be the third anti-TNF biosimilar in Biogen’s portfolio in Europe.

Read more 
Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance

Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance

21 Jun 2017

AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance.

Read more 
FDA accepts Amgen's sBLA to expand indication for Xgeva to include multiple myeloma patients

FDA accepts Amgen's sBLA to expand indication for Xgeva to include multiple myeloma patients

19 Jun 2017

Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumours and is the number one prescribed agent by oncologists for this indication in the US.

Read more 
Merck presses the pause button on Keytruda trials

Merck presses the pause button on Keytruda trials

16 Jun 2017

The pause is to allow for additional information to be collected to better understand more reports of death in the Keytruda groups.

Read more 
Parexel and Sanofi collaborate to advance the use of wearable devices in life science industry

Parexel and Sanofi collaborate to advance the use of wearable devices in life science industry

15 Jun 2017

Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently.

Read more 
Lilly's Taltz shows promise for patients with active psoriatic arthritis

Lilly's Taltz shows promise for patients with active psoriatic arthritis

15 Jun 2017

Demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors.

Read more 
LifeArc, previously MRC Technology, set to transform the medical research landscape

LifeArc, previously MRC Technology, set to transform the medical research landscape

15 Jun 2017

Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases.

Read more 
Irvine Scientific adds new Center of Excellence for R&D

Irvine Scientific adds new Center of Excellence for R&D

14 Jun 2017

Company adds fifth building in Southern California.

Read more